Kneat: Streamlining Compliance in Life Sciences

Digital validation software gains traction across major pharmaceutical giants

In an industry where every step must be documented and regulatory compliance is non-negotiable, Kneat is helping life sciences companies reduce costs and improve accuracy. Their digital validation platform has become the go-to choice for eight of the ten largest pharmaceutical companies worldwide. With customers like Merck rolling out Kneat across 27 global sites and over 12,000 users, the company is scaling rapidly. Offering a significant reduction in cycle time, documentation labor, and compliance errors, Kneat has seen its revenue climb 32% year-over-year in 2025. And with market penetration still low, the $2B total addressable market for digital validation remains largely untapped.

For more information on Kneat.com, Inc. (TSX: KSI, OTC: KSIOF) please click on the request investor info button.